Stress cardiomyopathy secondary prevention

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Stress cardiomyopathy Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stress Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Unstable angina/non ST elevation myocardial infarction in Stress (Takotsubo) Cardiomyopathy

Future or Investigational Therapies

Case Studies

Case #1

Stress cardiomyopathy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stress cardiomyopathy secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stress cardiomyopathy secondary prevention

CDC on Stress cardiomyopathy secondary prevention

Stress cardiomyopathy secondary prevention in the news

Blogs on Stress cardiomyopathy secondary prevention

Directions to Hospitals Treating Stress cardiomyopathy

Risk calculators and risk factors for Stress cardiomyopathy secondary prevention

Overview

Stress cardiomyopathy is a self-limiting disease, which usually resolves within a few weeks. However, medical therapy may be necessary during the acute phase of the illness or when complications arise.

Secondary Prevention

References

  1. Brunetti ND, Santoro F, De Gennaro L, Correale M, Kentaro H, Gaglione A, Di Biase M (2016). "Therapy of stress (takotsubo) cardiomyopathy: present shortcomings and future perspectives". Future Cardiol. 12 (5): 563–72. doi:10.2217/fca-2016-0014. PMID 27538839.

Template:WHTemplate:WS